

# WHAT'S NEXT FOR GAVI'S VACCINE INVESTMENT STRATEGY

---

# Rabies

Dr Bernadette ABELA-RIDDER  
Team Leader, Neglected Zoonotic Diseases  
Department of the Control of Neglected Tropical Diseases  
[abelab@who.int](mailto:abelab@who.int)



# Rabies at a glance

## VIRUS TRANSMISSION



Saliva of infected animals



99% of human cases are caused by **dog bites**

The virus attacks the brain  
Rabies is **fatal**  
once symptoms appear




## TREATMENT



**Post bite treatment saves lives**

Wash wound immediately and seek medical advice for wound care and vaccine  $\pm$ RIG



## FATALITIES

Rabies affects **poor rural communities** mostly in Asia and Africa



About **One death** every



**40%** of the victims are children younger than 15

## HOW TO PREVENT RABIES TRANSMISSION FROM DOGS?



Raise public **awareness**

Learn **dog body language**



**NO DOG BITE = NO RABIES**

## VACCINATING DOGS SAVES HUMAN LIVES

**Rabies is 100% preventable**



Vaccinating **70%** of dogs **breaks rabies transmission cycle** in an area at risk

Every dog owner is concerned



Zero  
human  
rabies  
deaths  
by  
2030



World Health Organization

# GAVI Vaccine Investment Strategy 2008 – 2013

- Critical knowledge gaps
  - Current level of rabies vaccine provision
  - i.d. versus i.m., wastage
  - RIG?
  - Treatment seeking behaviour
  - Treatment compliance
  - Barriers to access
- Decision to invest in research:
  - feasibility of Gavi support and logistic requirements of increasing access for PEP in existing programmatic experiences
  - Estimate (vaccine-preventable) rabies burden and vaccination impact in endemic Gavi countries

# Addressing the gaps by building the evidence base - GAVI Research Agenda

- Understanding unmet need, creating demand and building forecasts
  - Prospective and retrospective studies to address gaps in Chad, Côte d'Ivoire, Mali (Swiss TPH)
  - WHO facilitate leveraging of existing country data and prospective studies, with a focus on Asian countries
  - Spin off: other interested parties replicating studies in other countries to inform VIS

Building a business plan to support investment in discussion with countries, public, private and civil society partners

# Countering status quo

- intradermal administration (cost and vaccine saving)
- nervous tissue vaccine almost phased out
- Game changers? Potential supplier with thermostable vaccine, innovative delivery
- Review public health use of RIG
  - cost↑ - supply↓ - Quality assurance? - Evidence base of efficacy↓
- Evidence for reducing doses and schedule
- Community engagement
- Pooled procurement mechanism

# By 2018

Sufficient evidence for

- the need for rabies PEP
- the added value of Gavi support

To inform an evidenced based Gavi decision

***'There are many important initiatives under way to better children's lives but I believe that few can make a difference as quickly as the Global Alliance and the Fund have done'***

Nelson Mandela at Vaccine Conference, April 2002

